Could a statin tame fatty liver disease? new trial seeks answers
NCT ID NCT04679376
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether atorvastatin (Lipitor), a widely used cholesterol medication, can safely improve liver damage in people with NASH, a serious fatty liver disease. About 70 adults with confirmed NASH and liver scarring will receive either the drug or a placebo. The goal is to see if the drug can reduce liver inflammation and scarring without making the disease worse.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NASH - NONALCOHOLIC STEATOHEPATITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Duke University Medical Center
Durham, North Carolina, 27710, United States
-
Mayo Clinic Minnesota
Rochester, Minnesota, 55905, United States